DATA GRAPHICS | Data Byte
Pfizer’s Nurtec could become first blockbuster CGRP inhibitor
Oral migraine therapies Nurtec, Ubrelvy pull ahead of Lilly’s Emgality in 2023
February 9, 2024 2:09 AM UTC
The migraine field is crowded, but sales of six of the seven approved CGRP inhibitors managed to grow in 2023. The leader, Pfizer’s Nurtec, appears on track to become the class’ first blockbuster next year.
Together, the CGRP class brought in $3.8 billion in 2023 revenue, up 21% from 2022, with all but one of the individual products posting an annual gain...